首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Protective Effects of Chinese Traditional Medicine Longhu Rendan against Atherosclerosis via Negative Regulation of LOX-1
【24h】

Protective Effects of Chinese Traditional Medicine Longhu Rendan against Atherosclerosis via Negative Regulation of LOX-1

机译:龙湖林丹对洛克-1负调节龙湖龙湖林丹抗动脉粥样硬化的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Longhu Rendan (LHRD), a Chinese traditional compound medicine, has a remarkable treatment effect on motion sickness for about half a century. However, the role of LHRD in atherosclerosis treatment is still unclear. In this study, LHRD treatment significantly diminished total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels in apolipoprotein E gene-knockout (ApoE(-/-)) mice fed with high fat and high cholesterol diet (western diet). Besides, LHRD treatment significantly reduced atherosclerotic lesion and plaques formation in both aortic roots and aortic trees. Furthermore, immunofluorescence staining in aortic roots demonstrated that LHRD treatment inhibited lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) expression in atherosclerotic plaques. These results indicated that LHRD ameliorated atherosclerosis via reducing serum levels of TC, TG, and LDL-C as well as LOX-1 expression, subsequently attenuating atherosclerotic lesion and lipid deposition. In conclusion, LHRD could significantly attenuate experimental atherosclerosis and might be a novel potential drug for the prevention and treatment of atherosclerosis.
机译:中国传统复合医学龙湖林丹(LHRD)对大约半个世纪的晕车效果显着疗效。然而,LHRD在动脉粥样硬化治疗中的作用仍然不清楚。在本研究中,LHRD治疗在饲喂高脂肪喂养的载脂蛋白E基因敲除(ApoE( - / - ))小鼠中显着降低了总胆固醇(Tc),甘油三酯(Tg)和低密度脂蛋白胆固醇(LDL-C)水平和高胆固醇饮食(西方饮食)。此外,LHRD治疗在主动脉根和主动脉树中的动脉粥样硬化病变和斑块形成显着降低。此外,主动脉根部的免疫荧光染色证明了LHRD处理在动脉粥样硬化斑块中抑制凝集素状的氧化低密度 - 脂蛋白受体-1(LOX-1)表达。这些结果表明,LHRD通过减少Tc,Tg和LdL-C以及LOX-1表达的血清水平而改善动脉粥样硬化,随后衰减动脉粥样硬化病变和脂质沉积。总之,LHRD可显着衰减实验动脉粥样硬化,可能是一种用于预防和治疗动脉粥样硬化的新型潜在药物。

著录项

  • 来源
  • 作者单位

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Nanjing Med Univ Key Lab Cardiovasc Dis Nanjing 211166 Jiangsu Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Shanghai Zhonghua Pharmaceut Co Ltd Shanghai 201707 Peoples R China;

    Shanghai Zhonghua Pharmaceut Co Ltd Shanghai 201707 Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

    Guangdong Pharmaceut Univ Guangzhou 510006 Guangdong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 临床医学;
  • 关键词

  • 入库时间 2022-08-20 03:06:27

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号